The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice | Ophthalmology Times - Clinical Insights for Eye Specialists

Summary: Imagine losing your central vision and finding out the usual eye shots don't work well. That is the reality for people with an eye disease called MacTel (macular telangiectasia type 2). For a long time, doctors relied on standard injections called anti-VEGF, but they just weren't doing the trick.

Now, there is exciting news! Top eye doctors recently shared a podcast about a brand-new treatment: a cell-based gene therapy that actually protects the nerves in the eye. Doctors Dante Pieramici, Dean Eliott, and Charles Wykoff explained how this new therapy could change the game for patients. They discussed why old treatments fall short and how eye specialists can start using this new science in real life to save people's vision.

For more details, see rssapp-ophthalmologytimes-com at ophthalmologytimes.com/view/the-evolution-of-mactel-management-integrating-neuroprotective-therapies-into-clinical-practice (opens in new tab)